Discounted Cash Flow
Pfizer Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $7.2b | $14.1b | — | $1.17 |
| 2017 | — | $21.3b (195.3%) | $14.5b (3.1%) | — | $3.52 (200.9%) |
| 2018 | — | $11.2b (-47.7%) | $13.8b (-5.0%) | — | $1.86 (-47.2%) |
| 2019 | — | $16.3b (45.9%) | $10.4b (-24.5%) | — | $2.87 (54.3%) |
| 2020 | — | $9.6b (-40.9%) | $12.2b (16.7%) | — | $1.24 (-56.8%) |
| 2021 | $7.7b | $22.0b (128.6%) | $29.9b (145.8%) | 287.2% | $3.93 (216.9%) |
| 2022 | $8.5b (11.6%) | $31.4b (42.7%) | $26.0b (-12.8%) | 367.5% (27.9%) | $5.47 (39.2%) |
| 2023 | $7.6b (-11.2%) | $2.1b (-93.2%) | $4.8b (-81.6%) | 27.9% (-92.4%) | $0.37 (-93.2%) |
| 2024 | $8.4b (10.6%) | $8.0b (279.0%) | $9.8b (105.2%) | 95.7% (242.6%) | $1.41 (281.1%) |
| 2025 | $9.3b (10.5%) | $7.8b (-3.2%) | $9.1b (-7.7%) | 83.9% (-12.4%) | $1.36 (-3.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.